Loading…
Neogenomics Inc
Neogenomics Inc (NEO) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Fort Myers, United States and has 2,500 employees. The company is worth $2.11B. Revenue was $727.33M in fiscal 2025, up 10.1% from the year before. It reported a net loss of $108.03M. The share price is 18.7% below its 52-week high of $20.15. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $44.93M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -51.4% over 5Y.
today you would have $361.96▼ -63.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $11.76 | $16.48 | $16.18 | $9.24 | $34.12 | $53.84 | $29.25 | $12.61 | $8.86 | $8.57 | $7.87 | $4.17 | $3.62 | $2.48 | $1.40 | $1.30 | |
| P/E | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INSPInspire Medical Systems, Inc. | $72.66 | 16.0x | 2.5x | 0.00% | 17.96% | $2.1B |
| HRMYHarmony Biosciences Holdings, Inc. | $36.03 | 12.3x | 2.1x | 0.00% | 20.46% | $2.1B |
| VERAVera Therapeutics, Inc. | $29.05 | — | 5.1x | 0.00% | -91.75% | $2.09B |
| SGRYSurgery Partners, Inc. |
| — |
| — |
| — |
| — |
| 1442.7x |
| 378.6x |
| 437.4x |
| — |
| — |
| — |
| 208.5x |
| 90.5x |
| — |
| — |
| — |
| P/S | 5.9x | 2.1x | 3.2x | 3.5x | 2.3x | 8.7x | 14.2x | 7.5x | 4.3x | 3.0x | 2.9x | 119.4x | 50.3x | 35.6x | 22.5x | — | — |
| P/B | 4.2x | 1.8x | 2.3x | 2.2x | 1.2x | 3.8x | 9.1x | 6.0x | 3.7x | 4.1x | 4.2x | 2.9x | 4.2x | 8.2x | 12.2x | 10.6x | 15.5x |
| EPS | -$0.84 | -$0.62 | -$0.70 | -$1.16 | -$0.07 | $0.04 | $0.08 | $0.03 | -$0.00 | -$0.08 | -$0.04 | $0.02 | $0.04 | $0.00 | -$0.03 | -$0.09 |
| Profit margin | -0.94% | -14.85% | -11.92% | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.16% | -2.65% | -50.70% | 22.64% | 40.66% | 1.30% | — | — |
| ROE | -0.98% | -12.91% | -8.72% | -9.34% | -14.45% | -0.75% | 0.60% | 1.58% | 0.82% | -0.23% | -3.78% | -1.22% | 1.87% | 9.36% | 0.71% | -19.96% | -105.36% |
Median of the years shown; P/E years above 200x are left out.
| $15.90 |
| — |
| 1.2x |
| 0.00% |
| 2.32% |
| $2.08B |
| AXGNAxogen, Inc. | $36.68 | — | 7.7x | 0.00% | -18.21% | $2.15B |
| PHVSPharvaris N.V. | $30.68 | — | 6.4x | 0.00% | -70.46% | $2.15B |